These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37037866)

  • 1. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike.
    Tan TJC; Mou Z; Lei R; Ouyang WO; Yuan M; Song G; Andrabi R; Wilson IA; Kieffer C; Dai X; Matreyek KA; Wu NC
    Nat Commun; 2023 Apr; 14(1):2003. PubMed ID: 37037866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike.
    Tan TJC; Mou Z; Lei R; Ouyang WO; Yuan M; Song G; Andrabi R; Wilson IA; Kieffer C; Dai X; Matreyek KA; Wu NC
    bioRxiv; 2022 Sep; ():. PubMed ID: 36203547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
    Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
    mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens.
    Nuqui X; Casalino L; Zhou L; Shehata M; Wang A; Tse AL; Ojha AA; Kearns FL; Rosenfeld MA; Miller EH; Acreman CM; Ahn SH; Chandran K; McLellan JS; Amaro RE
    Nat Commun; 2024 Aug; 15(1):7370. PubMed ID: 39191724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    Brunet J; Choucha Z; Gransagne M; Tabbal H; Ku M-W; Buchrieser J; Fernandes P; Batalie D; Lopez J; Ma L; Dufour E; Simon E; Hardy D; Petres S; Guinet F; Strick-Marchand H; Monot M; Charneau P; Majlessi L; Duprex WP; Gerke C; Martin A; Escriou N
    J Virol; 2024 May; 98(5):e0169323. PubMed ID: 38563763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.
    Hsieh CL; Leist SR; Miller EH; Zhou L; Powers JM; Tse AL; Wang A; West A; Zweigart MR; Schisler JC; Jangra RK; Chandran K; Baric RS; McLellan JS
    Nat Commun; 2024 Feb; 15(1):1553. PubMed ID: 38378768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
    Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
    Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.
    Ellis D; Brunette N; Crawford KHD; Walls AC; Pham MN; Chen C; Herpoldt KL; Fiala B; Murphy M; Pettie D; Kraft JC; Malone KD; Navarro MJ; Ogohara C; Kepl E; Ravichandran R; Sydeman C; Ahlrichs M; Johnson M; Blackstone A; Carter L; Starr TN; Greaney AJ; Lee KK; Veesler D; Bloom JD; King NP
    Front Immunol; 2021; 12():710263. PubMed ID: 34267764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.
    Amanat F; Strohmeier S; Rathnasinghe R; Schotsaert M; Coughlan L; García-Sastre A; Krammer F
    mBio; 2021 Mar; 12(2):. PubMed ID: 33653892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity.
    Rutten L; Swart M; Koornneef A; Bouchier P; Blokland S; Sadi A; Juraszek J; Vijayan A; Schmit-Tillemans S; Verspuij J; Choi Y; Daal CE; Perkasa A; Torres Morales S; Myeni SK; Kikkert M; Tolboom J; van Manen D; Kuipers H; Schuitemaker H; Zahn R; Langedijk JPM
    Sci Rep; 2024 Mar; 14(1):5735. PubMed ID: 38459086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prefusion spike protein stabilization through computational mutagenesis.
    Zhang DY; Wang J; Dokholyan NV
    Proteins; 2021 Apr; 89(4):399-408. PubMed ID: 33231324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spike Mutation Profiles Associated With SARS-CoV-2 Breakthrough Infections in Delta Emerging and Predominant Time Periods in British Columbia, Canada.
    Fibke CD; Joffres Y; Tyson JR; Colijn C; Janjua NZ; Fjell C; Prystajecky N; Jassem A; Sbihi H
    Front Public Health; 2022; 10():915363. PubMed ID: 35859775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.
    Ávila-Nieto C; Vergara-Alert J; Amengual-Rigo P; Ainsua-Enrich E; Brustolin M; Rodríguez de la Concepción ML; Pedreño-Lopez N; Rodon J; Urrea V; Pradenas E; Marfil S; Ballana E; Riveira-Muñoz E; Pérez M; Roca N; Tarrés-Freixas F; Carabelli J; Cantero G; Pons-Grífols A; Rovirosa C; Aguilar-Gurrieri C; Ortiz R; Barajas A; Trinité B; Lepore R; Muñoz-Basagoiti J; Perez-Zsolt D; Izquierdo-Useros N; Valencia A; Blanco J; Clotet B; Guallar V; Segalés J; Carrillo J
    Front Immunol; 2023; 14():1291972. PubMed ID: 38124756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines.
    Lee J; Stewart C; Schäfer A; Leaf EM; Park YJ; Asarnow D; Powers JM; Treichel C; Sprouse KR; Corti D; Baric R; King NP; Veesler D
    Nat Commun; 2024 Jun; 15(1):5496. PubMed ID: 38944664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.